Skip to content

Study · Animal study (in vivo) · rat · 2004

8 results

Prolyl-leucyl-glycinamide shares some effects with oxytocin but decreases oxytocin levels.

Petersson M, Uvnäs-Moberg K

Physiology & behavior1 Dec 2004Cited by 7 (Europe PMC)

PMID15581670 (opens in a new tab)DOI10.1016/j.physbeh.2004.08.034 (opens in a new tab)PepBankPUB-15581670
Publisher pagePubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

6 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In male rats, PLG at 2 mg/kg decreased diastolic blood pressure (p<0.05).

    In plain wordsIn male rats, PLG at 2 mg/kg lowered diastolic blood pressure.

    Peptide
    MIF-1 (Pro-Leu-Gly-NH2)
    Outcome
    DecreaseDiastolic blood pressure at 2 mg/kg
    Study

    ratn: not reported in source

    male rats
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    2 mg/kg · subcutaneous · once daily for 3 or 5 daysAs given in this study (rat).

    Source sentences

    Summary
    PLG (2 mg/kg, s.c., but not 10 mg/kg, s.c.) decreased diastolic blood pressure (p<0.05) and locomotor activity (p<0.05).
    2 context sentences
    Summary · context
    This study investigated whether prolyl-leucyl-glycinamide (PLG) (the c-terminal tripeptide of oxytocin) or tocinoic acid (the ring structure of oxytocin) could induce some of these effects in male rats.
    Summary · context
    For this purpose, PLG (2 or 10 mg/kg, s.c.) or tocinoic acid (1 mg/kg, s.c.) was administered to rats once a day for 3 or 5 days.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In male rats, PLG at 10 mg/kg did not decrease diastolic blood pressure.

    In plain wordsIn male rats, PLG at 10 mg/kg did not lower diastolic blood pressure.

    Peptide
    MIF-1 (Pro-Leu-Gly-NH2)
    Outcome
    No significant changeDiastolic blood pressure at 10 mg/kg
    Study

    ratn: not reported in source

    male rats
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    10 mg/kg · subcutaneous · once daily for 3 or 5 daysAs given in this study (rat).

    Source sentences

    Summary
    PLG (2 mg/kg, s.c., but not 10 mg/kg, s.c.) decreased diastolic blood pressure (p<0.05) and locomotor activity (p<0.05).
    2 context sentences
    Summary · context
    This study investigated whether prolyl-leucyl-glycinamide (PLG) (the c-terminal tripeptide of oxytocin) or tocinoic acid (the ring structure of oxytocin) could induce some of these effects in male rats.
    Summary · context
    For this purpose, PLG (2 or 10 mg/kg, s.c.) or tocinoic acid (1 mg/kg, s.c.) was administered to rats once a day for 3 or 5 days.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In male rats, PLG at 2 mg/kg decreased locomotor activity (p<0.05).

    In plain wordsIn male rats, PLG at 2 mg/kg reduced movement.

    Peptide
    MIF-1 (Pro-Leu-Gly-NH2)
    Outcome
    DecreaseLocomotor activity at 2 mg/kg
    Study

    ratn: not reported in source

    male rats
    Outcome group
    Exercise and physical function · Nervous system and cognition
    Studied dose
    2 mg/kg · subcutaneous · once daily for 3 or 5 daysAs given in this study (rat).

    Source sentences

    Summary
    PLG (2 mg/kg, s.c., but not 10 mg/kg, s.c.) decreased diastolic blood pressure (p<0.05) and locomotor activity (p<0.05).
    2 context sentences
    Summary · context
    This study investigated whether prolyl-leucyl-glycinamide (PLG) (the c-terminal tripeptide of oxytocin) or tocinoic acid (the ring structure of oxytocin) could induce some of these effects in male rats.
    Summary · context
    For this purpose, PLG (2 or 10 mg/kg, s.c.) or tocinoic acid (1 mg/kg, s.c.) was administered to rats once a day for 3 or 5 days.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In male rats, PLG at 10 mg/kg did not decrease locomotor activity.

    In plain wordsIn male rats, PLG at 10 mg/kg did not reduce movement.

    Peptide
    MIF-1 (Pro-Leu-Gly-NH2)
    Outcome
    No significant changeLocomotor activity at 10 mg/kg
    Study

    ratn: not reported in source

    male rats
    Outcome group
    Exercise and physical function · Nervous system and cognition
    Studied dose
    10 mg/kg · subcutaneous · once daily for 3 or 5 daysAs given in this study (rat).

    Source sentences

    Summary
    PLG (2 mg/kg, s.c., but not 10 mg/kg, s.c.) decreased diastolic blood pressure (p<0.05) and locomotor activity (p<0.05).
    2 context sentences
    Summary · context
    This study investigated whether prolyl-leucyl-glycinamide (PLG) (the c-terminal tripeptide of oxytocin) or tocinoic acid (the ring structure of oxytocin) could induce some of these effects in male rats.
    Summary · context
    For this purpose, PLG (2 or 10 mg/kg, s.c.) or tocinoic acid (1 mg/kg, s.c.) was administered to rats once a day for 3 or 5 days.
  5. 05AnimalAnimal study (in vivo)Mechanism

    In male rats, PLG at 10 mg/kg decreased gastrin levels (p<0.05).

    In plain wordsIn male rats, PLG at 10 mg/kg lowered gastrin levels.

    Peptide
    MIF-1 (Pro-Leu-Gly-NH2)
    Outcome
    DecreaseGastrin levels
    Study

    ratn: not reported in source

    male rats
    Outcome group
    Endogenous peptide levels · Endocrine and hormones
    Studied dose
    10 mg/kg · subcutaneous · once daily for 3 or 5 daysAs given in this study (rat).

    Source sentences

    Summary
    PLG (10 mg/kg, s.c.) decreased gastrin (p<0.05) and endogenous oxytocin levels in plasma (p<0.01).
    2 context sentences
    Summary · context
    This study investigated whether prolyl-leucyl-glycinamide (PLG) (the c-terminal tripeptide of oxytocin) or tocinoic acid (the ring structure of oxytocin) could induce some of these effects in male rats.
    Summary · context
    For this purpose, PLG (2 or 10 mg/kg, s.c.) or tocinoic acid (1 mg/kg, s.c.) was administered to rats once a day for 3 or 5 days.
  6. 06AnimalAnimal study (in vivo)Mechanism

    In male rats, PLG at 10 mg/kg decreased endogenous plasma oxytocin levels (p<0.01).

    In plain wordsIn male rats, PLG at 10 mg/kg lowered the body's own oxytocin levels in blood.

    Peptide
    MIF-1 (Pro-Leu-Gly-NH2)
    Outcome
    DecreaseEndogenous plasma oxytocin levels
    Study

    ratn: not reported in source

    male rats
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones
    Studied dose
    10 mg/kg · subcutaneous · once daily for 3 or 5 daysAs given in this study (rat).

    Source sentences

    Summary
    PLG (10 mg/kg, s.c.) decreased gastrin (p<0.05) and endogenous oxytocin levels in plasma (p<0.01).
    2 context sentences
    Summary · context
    This study investigated whether prolyl-leucyl-glycinamide (PLG) (the c-terminal tripeptide of oxytocin) or tocinoic acid (the ring structure of oxytocin) could induce some of these effects in male rats.
    Summary · context
    For this purpose, PLG (2 or 10 mg/kg, s.c.) or tocinoic acid (1 mg/kg, s.c.) was administered to rats once a day for 3 or 5 days.

Natural levels measured2

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 07AnimalEndogenous levelAnimal study (in vivo)Mechanism

    In male rats, prolyl-leucyl-glycinamide 10 mg/kg s.c. lowered the body's own plasma oxytocin levels.

    In plain wordsIn male rats, a high dose of the compound PLG lowered the body's own oxytocin levels in blood.

    Peptide
    Oxytocin
    Outcome
    DecreasePlasma endogenous oxytocin after PLG 10 mg/kg
    Study

    ratn: not reported in source

    Outcome group
    Sex hormones and fertility · Endocrine and hormones

    Source sentences

    Summary
    PLG (10 mg/kg, s.c.) decreased gastrin (p<0.05) and endogenous oxytocin levels in plasma (p<0.01).
    1 context sentence
    Summary · context
    For this purpose, PLG (2 or 10 mg/kg, s.c.) or tocinoic acid (1 mg/kg, s.c.) was administered to rats once a day for 3 or 5 days.

    This result measures the body's own Oxytocin. Nobody was given the peptide. It is not evidence about taking it.

  2. 08AnimalEndogenous levelAnimal study (in vivo)Mechanism

    In male rats, tocinoic acid 1 mg/kg s.c. did not affect the body's own plasma oxytocin levels, which were among the parameters measured.

    In plain wordsIn male rats, the compound tocinoic acid did not change the body's own oxytocin levels in blood.

    Peptide
    Oxytocin
    Outcome
    No significant changePlasma endogenous oxytocin after tocinoic acid 1 mg/kg
    Study

    ratn: not reported in source

    Outcome group
    Sex hormones and fertility · Endocrine and hormones

    Source sentences

    Summary
    Tocinoic acid decreased locomotor activity (p<0.05), but did not affect any of the other parameters measured.
    1 context sentence
    Summary · context
    In addition, endogenous oxytocin levels and plasma levels of some hormones known to be influenced by oxytocin were determined.

    This result measures the body's own Oxytocin. Nobody was given the peptide. It is not evidence about taking it.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Versions 4 to 9Current

    28 Oct 2026, 02:03 UTC

    The same notice was added 6 times, first on 22 Oct 2026, 02:26 UTC. The status did not change between them.

    Study results updated

  2. Version 3

    21 Oct 2026, 18:59 UTC

    Study data updated · source update from Europe PMC

  3. Version 2

    11 Oct 2026, 20:03 UTC

    Study results updated

  4. Version 1

    9 Oct 2026, 02:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.